Analyzing the IMvigor210 cohort20,21, we determined that the degree of response to anti-PD-L1 inhibitors, including complete response (CR), partial response (PR), stable disease (SD), or progressive disease (PD), was linked to GBM scores. Here, CD274 is linked to glioblastoma.